Of course there’s still some ambiguity. They’re likely investigating many things in parallel right now and cautiously assessing impact and scope. Their language suggests they think they’ve got the full picture, but they’re likely still exploring some niche areas to be safe.

They’ve given public statements on the general area of the issue and its limited scope. I think your expectations on this issue at this point about perfect transparency are a bit unrealistic for a publicly traded company.